Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.

Efficacy and safety of switching to ixekizumab in secukinumab nonresponder psoriatic patients: results from a multicenter experience

Amerio, P;
2019-01-01

Abstract

Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.
File in questo prodotto:
File Dimensione Formato  
bjd1547.pdf

Solo gestori archivio

Tipologia: PDF editoriale
Dimensione 194.35 kB
Formato Adobe PDF
194.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/699455
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 25
social impact